Get the Stockscreener App
1.77
1.39%
-0.025
After Hours:
1.75
-0.02
-1.13%
Gain Therapeutics Inc stock is traded at $1.77, with a volume of 122.20K.
It is down -1.39% in the last 24 hours and down -5.85% over the past month.
Gain Therapeutics Inc is a biotechnology company developing novel small molecule therapeutics to treat diseases across several therapeutic areas, including, lysosomal storage disorders, central nervous system disorders, metabolic disorders, and oncology. The company's clinical-stage product candidate, GT-02287, is being developed for the treatment of GBA1 Parkinson's disease. The company uses its computational target and drug discovery platform, Magellan, to discover novel allosteric binding sites on proteins implicated in disease and to identify proprietary small molecules that bind these sites to modulate protein function and treat the underlying cause of the disease. Geographically, the company operates in Switzerland, Spain, the United States, and Australia.
See More
Previous Close:
$1.795
Open:
$1.78
24h Volume:
122.20K
Relative Volume:
0.47
Market Cap:
$52.32M
Revenue:
$210.70K
Net Income/Loss:
$-21.37M
P/E Ratio:
-1.6091
EPS:
-1.1
Net Cash Flow:
$-21.10M
1W Performance:
-1.67%
1M Performance:
-5.85%
6M Performance:
-4.84%
1Y Performance:
-29.48%
1-Day Range:
$1.76
$1.825
1-Week Range:
$1.74
$1.85
52-Week Range:
$0.89
$3.19
Gain Therapeutics Inc Stock (GANX) Company Profile
Name
Gain Therapeutics Inc
Sector
Industry
Phone
(301) 500-1556
Address
4800 HAMPDEN LANE, BETHESDA
Compare GANX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GANX
Gain Therapeutics Inc
|
1.77 | 53.20M | 210.70K | -21.37M | -21.10M | -1.10 |
|
ONC
Beone Medicines Ltd Adr
|
245.58 | 26.10B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
442.05 | 111.96B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 42.96M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
81.20 | 6.39B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
490.28 | 63.52B | 14.09B | 4.50B | 2.96B | 39.28 |
Gain Therapeutics Inc Stock (GANX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-07-25 | Initiated | Scotiabank | Sector Outperform |
| Dec-06-24 | Initiated | ROTH MKM | Buy |
| Aug-14-24 | Resumed | Oppenheimer | Outperform |
| Apr-12-21 | Initiated | BTIG Research | Buy |
| Apr-12-21 | Initiated | Oppenheimer | Outperform |
Gain Therapeutics Inc Stock (GANX) Latest News
Lantern Pharma Inc. (LTRN)’s LP-184 Shows 345% Survival Gain in Rare Pediatric Brain Tumor Models - Yahoo Finance
Gain Therapeutics, Inc. Announces Oral Presentation at GBA1 Meeting 2025 in Montreal - Nasdaq
Gain Therapeutics' Chief Medical Officer Set to Reveal Latest GBA1 Therapeutic Developments in Montreal - Stock Titan
Gain Therapeutics Files $100 Million Mixed Shelf - marketscreener.com
Gain Therapeutics (GANX) Pursues $100 Million Securities Offerin - GuruFocus
Gain Therapeutics (GANX) Pursues $100 Million Securities Offering | GANX Stock News - GuruFocus
US Stocks Gain; Abercrombie & Fitch Posts Upbeat Earnings - Benzinga
CytomX Therapeutics Inc’s (CTMX) 4.41% Gain Is A Reason To Reconsider. - Stocksregister
HC Wainwright Brokers Increase Earnings Estimates for GANX - Defense World
Gotham Asset Management LLC Sells 176,437 Shares of Gain Therapeutics, Inc. (NASDAQ:GANX) - Defense World
Gain Therapeutics, Inc. (NASDAQ:GANX) Given Average Rating of “Buy” by Analysts - Defense World
GM1 Gangliosidosis Market: Epidemiology, Therapies, - openPR.com
Gain Therapeutics (NASDAQ:GANX) Receives Buy Rating from HC Wainwright - Defense World
Gain Therapeutics (GANX) Maintains 'Buy' Rating with $8 Price Ta - GuruFocus
Roth Capital Predicts Reduced Earnings for Gain Therapeutics - Defense World
Gain Therapeutics Reports Q1 2025 Financial Results - TipRanks
Gain Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Gain (GANX) Advances Parkinson's Treatment in Phase 1b Trials | - GuruFocus
Gain Therapeutics Reports Financial Results for First Quarter 2025 and Provides Corporate Update - The Manila Times
Gain Therapeutics, Inc. Reports Q1 2025 Financial Results and Corporate Update, Highlights Progress in Parkinson’s Disease Drug Development - Nasdaq
Gain Therapeutics' Parkinson's Drug Shows Promise: Key Biomarker Data Coming Mid-2025 - Stock Titan
Zevra Therapeutics Q1 Net Loss Narrows, Revenue Rises; Shares Gain After Hours - marketscreener.com
Crude Oil Gains 3%; US Inflation Eases In April - Benzinga
Gain Therapeutics (GANX) Showcases Promising Parkinson's Treatme - GuruFocus
Gain Therapeutics, Inc. Presents New Evidence for GT-02287 as Potential Disease-Modifying Therapy for Parkinson’s Disease at IAPRD 30th World Congress - Nasdaq
Gain Therapeutics Presents Preclinical Data at IAPRD 2025 30th World Congress on Parkinson's Disease and Related Disorders - The Manila Times
Gain Therapeutics Presents Preclinical Data at IAPRD 2025 30th World Congress on Parkinson’s Disease and Related Disorders - TradingView
Gain Therapeutics (GANX) Expected to Announce Earnings on Tuesday - Defense World
Halozyme Therapeutics, Inc. (HALO): Among the Best Cancer Stocks to Invest in for Long-Term Gain - Insider Monkey
Summit Therapeutics Inc. (SMMT): Among the Best Cancer Stocks to Invest in for Long-Term Gain - Yahoo Finance
Celldex Therapeutics, Inc. (CLDX): Among the Best Cancer Stocks to Invest in for Long-Term Gain - Yahoo Finance
TG Therapeutics, Inc. (TGTX): Among the Best Cancer Stocks to Invest in for Long-Term Gain - Yahoo Finance
Protagonist Therapeutics, Inc. (PTGX): Among the Best Cancer Stocks to Invest in for Long-Term Gain - Yahoo Finance
Gaining Ground: Verve Therapeutics Inc (VERV) Closes Lower at 5.95, Down -11.33 - DWinneX
Closing Figures Unveiled: Indaptus Therapeutics Inc (INDP) Gain 7.96, Closes at 0.71 - DWinneX
Market Insights: Trevi Therapeutics Inc (TRVI)’s Notable Gain of 1.22, Closing at 6.66 - DWinneX
Gain Therapeutics Inc (GANX) Performance and Fundamentals Dashboard tells a completely different story - Sete News
Market Watch: Soleno Therapeutics Inc (SLNO)’s Noteworthy Gain, Closing at 75.02 - DWinneX
Gain Therapeutics Inc [GANX] Records 50-Day SMA of $1.9700 - knoxdaily.com
Gaining Ground: SpringWorks Therapeutics Inc (SWTX) Closes Higher at 46.30, Up 0.13 - DWinneX
Gain Therapeutics Inc (GANX) Stock: Navigating Drops and Gains - investchronicle.com
Market Watch: ITeos Therapeutics Inc (ITOS)’s Noteworthy Gain, Closing at 7.25 - DWinneX
Gain Therapeutics to Participate at The Citizens Life Sciences Conference - Eagle-Tribune
Gain Therapeutics Inc (GANX) deserves deeper analysis - uspostnews.com
Gain Therapeutics CEO to Showcase Next-Gen Allosteric Therapies at Major Healthcare Conference - Stock Titan
Gain Therapeutics Announces Oral Poster Presentation - marketscreener.com
Gain Therapeutics Announces Oral Poster Presentation at IAPRD 2025 30th World Congress on Parkinson's Disease and Related Disorders - The Manila Times
Gain Therapeutics, Inc. Announces Oral Poster Presentation of GT-02287 for Parkinson's Disease at IAPRD 30th World Congress - Nasdaq
Breakthrough: Novel Drug GT-02287 Demonstrates Neuroprotective Effects in Parkinson's Disease - Stock Titan
Prediction: Pfizer's Loss May Be Viking Therapeutics' Gain - Yahoo Finance
Gaining Ground: Structure Therapeutics Inc ADR (GPCR) Closes Lower at 23.62, Down -0.51 - DWinneX
Gain Therapeutics Inc Stock (GANX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.89%
3.74%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):